Dominick Grosso
Internal Medicine · Red Bank, NJNPI 1568486249
Payments from drug & device makers
Across 100 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$440
- Johnson & Johnson$313
- Welch Allyn$216
- AstraZeneca$194
- Amgen$129
- Sanofi-aventis U.S. LLC$53
- plus $252 from 12 others
What the payments were for
- Food & beverage$1,38186%
- Gifts$21614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $440 |
| Johnson & Johnson | 24 | $313 |
| Welch Allyn | 1 | $216 |
| AstraZeneca | 14 | $194 |
| Amgen | 9 | $129 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| AbbVie | 3 | $41 |
| Abbott | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| Philips North America LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Indivior Inc. | 1 | $14 |
| Merck | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,597 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $12,450 |
| Rosuvastatin Calcium | 31 | $760 |
| Atorvastatin Calcium | 50 | $660 |
| Ezetimibe | 20 | $572 |
| Amlodipine Besylate | 63 | $478 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 17 | $442 |
| Irbesartan | 13 | $413 |
| Benazepril Hcl | 37 | $389 |
| Metoprolol Succinate | 17 | $337 |
| Pantoprazole Sodium | 22 | $302 |
| Carvedilol | 16 | $300 |
| Finasteride | 14 | $283 |
| Levothyroxine Sodium | 23 | $277 |
| Duloxetine Hcl | 11 | $266 |
| Paroxetine Hcl | 12 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $12,45018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Red Bank
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.